Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial.
The Lancet Oncology.
Times cited: 61
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Leukemia and Lymphoma.
Times cited: 15
Single agent bevacizumab for myelofibrosis: Results of the myeloproliferative disorders research consortium trial.
Times cited: 9
Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia.
British Journal of Haematology.
Times cited: 13